Evidence map›Paper›PMID 24425706›Full record

ArticleCirculation. Cardiovascular quality and outcomes2014

Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.

Miao Wang, Andrew E Moran, Jing Liu, Pamela G Coxson, Paul A Heidenreich, Dongfeng Gu, Jiang He, Lee Goldman, Dong Zhao

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Cardiovascular quality and outcomes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. A Review of Various Methods of Management of Risk in the Field of Emergency Medicine.Open access Macedonian journal of medical sciences · 2019
    Review
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Miao WangDepartment of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Andrew E Moran
Jing Liu
Pamela G Coxson
Paul A Heidenreich
Dongfeng Gu
Jiang He
Lee Goldman
Dong Zhao
Fu Wai Hospital · CNSan Francisco General Hospital · USStanford University · USTulane University · USColumbia University · US

Funding

Forecasting the Cardiovascular Disease Epidemic in ChinaK08HL089675 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MORAN, ANDREW EDWARD · 2008 to 2012
$650k
NHLBI NIH HHS K08 HL089675NHLBI NIH HHS K08HL089675
6 · The paper itself

Abstract

backgroundThe cost-effectiveness of the optimal use of hospital-based acute myocardial infarction (AMI) treatments and their potential impact on coronary heart disease (CHD) mortality in China is not well known. METHODS AND

resultsThe effectiveness and costs of optimal use of hospital-based AMI treatments were estimated by the CHD Policy Model-China, a Markov-style computer simulation model. Changes in simulated AMI, CHD mortality, quality-adjusted life years, and total healthcare costs were the outcomes. The incremental cost-effectiveness ratio was used to assess projected cost-effectiveness. Optimal use of 4 oral drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors) in all eligible patients with AMI or unfractionated heparin in non-ST-segment-elevation myocardial infarction was a highly cost-effective strategy (incremental cost-effectiveness ratios approximately US $3100 or less). Optimal use of reperfusion therapies in eligible patients with ST-segment-elevation myocardial infarction was moderately cost effective (incremental cost-effectiveness ratio ≤$10,700). Optimal use of clopidogrel for all eligible patients with AMI or primary percutaneous coronary intervention among high-risk patients with non-ST-segment-elevation myocardial infarction in tertiary hospitals alone was less cost effective. Use of all the selected hospital-based AMI treatment strategies together would be cost-effective and reduce the total CHD mortality rate in China by ≈9.6%.

conclusionsOptimal use of most standard hospital-based AMI treatment strategies, especially combined strategies, would be cost effective in China. However, because so many AMI deaths occur outside of the hospital in China, the overall impact on preventing CHD deaths was projected to be modest.

Indexed as

Adrenergic beta-AntagonistsAdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAspirinChinaClopidogrelComputer SimulationCoronary DiseaseCost-Benefit AnalysisElectrocardiographyHeparinHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAspirinClopidogrelHeparinHydroxymethylglutaryl-CoA Reductase InhibitorsTiclopidinecost-benefit analysismyocardial infarctionquality-adjusted life yearstherapy

Identifiers

PMID24425706
PMCPMC4191653
OpenAlexW2145983416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.